Thermo Fisher Scientific said on Monday that it has acquired Belgium-based PharmaFluidics, the developer of the μPAC range of microchip-based chromatography columns.

Bruker reported after the close of the market Monday that revenues in the third quarter rose 19 percent year over year.

Hologic reported after the close of the market on Monday that its fiscal fourth quarter revenues fell 2 percent year over year, driven by a drop in molecular diagnostic and COVID-19 assay sales.

Some of the neurological symptoms associated with menopause are similar to early signs of dementia. The ability of MHT to alleviate such symptoms in some women has led scientists to question whether a link exists between specific hormone levels and dementia.

The US Food and Drug Administration on Thursday said it has granted Emergency Use Authorization for Detect's over-the-counter, at-home SARS-CoV-2 test.

A few days ago, EUROIMMUN (PerkinElmer) formally completed the acquisition of British diagnostic company Immunodiagnostic Systems (IDS). In the future, IDS, as a new member of the PerkinElmer Group, will cooperate closely with EUROIMMUN in the fields of R&D, production, and sales.

CareDx reported after the close of the market on Thursday that its third quarter revenues rose 42 percent year over year, thanks largely to a 46 percent increase in testing service revenues during the quarter.

A newly developed coating that allows for certain liquids to move across surfaces without fluid loss could usher in new advances in a range of fields including medical testing.

Thermo Fisher Scientific reported before the opening of the market on Wednesday that its third quarter revenues rose 9 percent year over year, thanks to growth across three of its four business segments.

Researchers from Newcastle University, and colleagues from Spain, Canada and Egypt, have successfully trialled two new qPCR assays to help detect the presence of transmissible AMR using water and wastewater samples.

GenomSys said Wednesday that it has received CE marking for the GenomSys Variant Analyzer.

Autobio third quarter report of 2021 shows that in the first three quarters of this year, it achieved salse of CNY 2.695 billion, up 31.64% year on year. Autobio q3 net profit was CNY 717 million, up 39.33% year-on-year.

The US Food and Drug Administration last week granted Emergency Use Authorization for InBios International's SCoV-2 Detect Neutralizing Ab ELISA immunoassay for SARS-CoV-2.

People at risk from strokes and heart attacks could benefit from personalised clotting profiles to help clinicians prescribe more precise treatments, thanks to new research.

As a leading company of immunoassay solutions, YHLO’s core products have gained recognition from professionals in the field. Top Chinese hospitals including Fuwai Hospital, Peking Union Medical College Hospital (PUMCH), Beijing Hospital and more have been cooperating with YHLO for years.